LOVED BY SMART PEOPLE:

  • A refreshing change. BioPharma's dealmakers have waited too long for modern, intelligent and mobile friendly tools."

    ROBIN SHERRINGTON,
    SVP Business & Corporate Development, Xenon

  • Amazingly accurate, and in the case of the new indication has saved us a great deal of time and effort."

    PAUL BRENNAN,
    VP Business Development, Aquinox Pharmaceuticals

  • This is an elegant platform that optimizes outcomes for potential partners on both sides of a deal."

    ROD FERGUSON,
    Managing Director, Panorama Capital
    (Former Senior Director Business & Corporate Development, Genentech)

  • MotionHall is an up and coming company with a product to transform the dealmaking process."

    ERIC WALCZYKOWSKI,
    (Former VP Life Sciences, Thomson Reuters and Division President, Deloitte Recap)

 

ML Icon.png

WE INGEST MASSIVE DATASETS...

The strategies of world leading biopharma dealmakers are baked into our predictive technology, which organizes data into reports.

 


...TO IDENTIFY IDEAL PARTNERS...

Reports are uniquely tailored to your deal & presented with visual tools to help you work and build insights.

pipeline.png

...AND PROVIDE UNIQUE, PREDICTIVE INSIGHTS.

Use the OutMatch AI to see past opinion pieces, geographic boundaries and corporate messaging. Drive competition for your deal, improved financials and be confident in product success.


ADVANCED PARTNERING INSIGHTS FROM DATA

Save time and leverage your expertise with deep data-driven market intelligence you won't find anywhere else.

Check out this 2-minute video demonstrating MotionHall's out-licensing tools:

  • You'll learn about the unique types of information and insights offered by the MotionHall platform.
     
  • You'll see a predictive potential partners report based on a non-confidential model of Jounce's JTX-2011.

Fill out the form below to have the Demo video sent to your email inbox.

Name *
Name

Want to take OutMatch for a spin? Sign up for free, and receive an interactive sample based on Jounce's recent deal with Celgene.